stockrowVeracyte, Inc.
VCYT Healthcare Diagnostics & Research
Veracyte, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $517.1 million, up 16.0% from fiscal 2024.
- Revenue
- +15.1%
- EPS
- +62.5%
- Free cash flow
- −9.63%
Quarter to September 2026, against a year earlier
Follow VCYT
Alert me
Veracyte, Inc. (VCYT) EPS (diluted)
Veracyte, Inc.'s EPS (diluted) for fiscal 2025 was $0.82, up 164.5% from $0.31 in fiscal 2024. Over the twelve months to 30 September 2026 it was $1.55. Over the past ten years it has ranged from −$1.30 (fiscal 2015) to $0.82 (fiscal 2025) — the current reading is the highest in ten years. Veracyte, Inc. ranks 17th of 49 Diagnostics & Research companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $0.82 | 164.52% |
| FY2024 | $0.31 | — |
| FY2023 | −$1.02 | — |
| FY2022 | −$0.51 | — |
| FY2021 | −$1.11 | — |
| FY2020 | −$0.66 | — |
| FY2019 | −$0.27 | — |
| FY2018 | −$0.62 | — |
| FY2017 | −$0.91 | — |
| FY2016 | −$1.09 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $0.38 | 22.58% |
| Jun 2026 | $0.31 | (11.43%) |
| Mar 2026 | $0.35 | (31.37%) |
| Dec 2025 | $0.51 | 112.50% |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| CDNA CareDx, Inc. compare | $2.39 |
| VCYT Veracyte, Inc. | $1.55 |
| BLLN BillionToOne, Inc. compare | $0.92 |
| SHC Sotera Health Company compare | $0.60 |
| NEO NeoGenomics, Inc. compare | −$0.25 |
| RDNT RadNet, Inc. compare | −$0.27 |
| ADPT Adaptive Biotechnologies Corporation compare | −$0.45 |
| WGS GeneDx Holdings Corp. compare | −$3.64 |
| GRAL GRAIL, Inc. compare | −$9.50 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on VCYT
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement